A 42-year-old male underwent an HLA-matched sibling PBSC transplant for hypereosinophilic syndrome (HES) diagnosed in August 1995. Prior to transplant he experienced progressive cardiac and pulmonary dysfunction with red cell and platelet transfusion dependence despite therapy with hydroxyurea, steroids and interferon. He received busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) as conditioning and standard GVHD prophylaxis with cyclosporin A and methotrexate. At day +336 he was transfusion independent without GVHD. Prompt reduction of the eosinophil count (Ͻ500/l) and rapid improvement of cardiac function were documented, demonstrating the reversibility of organ dysfunction. Allogeneic PBSCT is an effective therapeutic option for patients with HES who fail conventional therapy.
The hypereosinophilic syndrome (HES) is characterized by a persistent idiopathic eosinophilia (Ͼ1500 eosinophils/l) with evidence of organ dysfunction. 1 HES may respond to conventional therapy with steroids, hydroxyurea, interferon and cyclosporin A. 1, 2 Normalization of the peripheral counts and regression of end organ damage indicate response to treatment. Failure of conventional treatment results in progressive end-organ dysfunction and death. The prognosis of patients with progressive disease is exceedingly poor with only 12% survival at 3 years. Five cases of allogeneic BMT have been reported with successful disease-free survival in three. [3] [4] [5] [6] [7] We report allogeneic PBSCT in a man with transfusion-dependent HES, restrictive cardiomyopathy and mixed obstructive and restrictive lung disease. 
Case report
A 42-year-old man was diagnosed with the hypereosinophilic syndrome in August 1995. He had persistent eosinophilia (Ͼ10 000/l), splenomegaly, endomyocardial fibroelastosis with severe mitral and tricuspid regurgitation, pulmonary hypertension and a mixed restrictive and obstructive pulmonary function defect. A bone marrow aspirate and biopsy revealed a hypercellular marrow with hyperplasia of the eosinophilic series, with fibrosis and a blast count of 3%. Cytogenetic study of the bone marrow on two separate occasions (23 May 1997 and 9 October 1995) was normal. Therapy with steroids was ineffective, as was subsequent therapy with steroids and hydroxyurea over a 3 month period. On this medication his peripheral counts deteriorated and he became dependent upon red blood cell and platelet transfusion. He had three separate episodes of life-threatening pulmonary edema during transfusion. Interferon and erythropoietin therapy were instituted in November 1995. Partial response was documented over the next 18 months with a decreased transfusion requirement, decreased eosinophil count, decreased splenomegaly, increased exercise tolerance and improved cardiac function on echocardiogram. However, none of these parameters normalized. By May 1997, his condition deteriorated with an increasing eosinophil count, increasing red blood cell transfusion frequency, falling platelet count and worsening exercise tolerance. Interferon therapy was stopped without improvement in hematological parameters. HLA-typing confirmed a compatible brother and peripheral blood stem cell transplantation was planned for July 1997. The transplant was delayed due to an episode of presumed bacterial pneumonia, which left the patient debilitated and with worsened pulmonary function. Prior to transplant he reported easy fatigability with a markedly reduced exercise tolerance and dyspnea at rest. FEV1 was 1.08 l, FEV1/FVC was 53%, TLC was 4.07 l with a DLCO of 9.8 ml/ min/mmHg (42% of predicted). An echocardiogram showed biatrial enlargement with mitral inflow restriction consistent with restrictive cardiomyopathy, left ventricular apical thrombus, moderate mitral regurgitation and mild tricuspid regurgitation. Immediately prior to transplant the total white count was 12 300/l with an absolute eosinophil count of 7200/l, the hemoglobin was 6.9 g/dl with a platelet count of 16 000/l. His ECOG performance status was 3.
The donor received G-CSF (16 g/kg/day) for 4 days prior to undergoing leukapheresis for the collection of PBSC on the fifth day. The graft contained 3.6 × 10 6 CD34
+ cells/kg of recipient body weight. The patient received busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) as conditioning and was transplanted on 2 January 1998. Standard GVHD prophylaxis was started with cyclosporin A and short-course methotrexate. Engraftment occurred on day +15 with an ANC Ͼ500/l and a fall in the eosinophil count to less than 2% (AEC 100/l). During a platelet transfusion on day +23 the patient became acutely short of breath with severe chest tightness. He was transferred to the ICU and was given i.v. steroids for presumed transfusion-related acute lung injury (TRALI). Subsequent transfusions with steroid premedication were uncomplicated. An echocardiogram was repeated on day +35, which demonstrated overall improved cardiac function with improvement of tricuspid regurgitation and he was discharged from hospital. A faint skin rash was noted on day +44, which on skin biopsy revealed grade 2 acute GVHD. Prednisone at 1 mg/kg/day was given with resolution of the rash, no GVHD of the gut or liver was documented. The prednisone was successfully tapered to a dose of 5 mg/day without a GVHD flare. A repeat bone marrow biopsy at day +100 showed mild eosinophilia and fibrosis, but was markedly improved as compared to a specimen obtained prior to transplant. RFLP analysis demonstrated 100% donor hematopoiesis at day +100. Blood counts at day +336 were WBC 5500/l, hemoglobin 15.4 g/dl, platelets 67 000/l and an absolute eosinophil count of 500/l. The patient's ECOG performance status was 1, at day +336.
Discussion
HES is considered a myeloproliferative disorder but in certain cases may be secondary to secretion of eosinophil cytokines from cells making up a clonal T cell proliferation. 2 In either case, hematopoietic stem cell transplantation potentially offers cure by eradication of the clonal disorder.
Our patient failed conventional therapy for HES and came to transplant with a markedly reduced performance status and cardiac and pulmonary dysfunction that would normally preclude transplantation. After transplantation he experienced a rapid improvement in cardiac function coincident with disappearance of the eosinophilia. As reported for allogeneic bone marrow transplantation, allogeneic PBSC transplantation is a feasible treatment for patients with a matched sibling and organ dysfunction due to HES. Further study of allogeneic PBSCT is warranted to define the optimal strategy for the treatment of this rare entity.
